Parabilis Medicines launched a zolucatetide dose-ranging cohort in familial adenomatous polyposis after early polyp ...

Takeda reported Phase 2/3 IgGNITE trial results showing TAK-881 may reduce infusion burden for primary immunodeficiency ...

Entrada Therapeutics will begin the 18 mg/kg cohort of its Phase 1/2 ENTR-601-44 Duchenne muscular dystrophy study after ...

Morgan Stanley reported Q3 2026 revenue of $20.34 billion, EPS of $3.03, and strong growth across trading and wealth ...

State Street reported Q3 2026 adjusted EPS of $3.69, beating estimates, with fee revenue reaching $3.14 billion. Meta Image ...

Entrada Therapeutics reported ENTR-601-45 met safety goals in a Phase 1/2 DMD study with early dystrophin and exon-skipping ...

Eton Pharmaceuticals entered U.S. licensing agreements for LIBERVANT, a seizure-cluster treatment expected to launch in 2027 ...

Sono-Tek reported fiscal first-half 2027 revenue of $10.9 million, driven by medical-device sales growth and improved ...

Bank of America reported Q3 2026 revenue of $29.96 billion and adjusted EPS of $1.08, impacted by a $1.2 billion regulatory ...

National Fuel Gas approved a plan to spin off its Integrated Upstream and Gathering business into a separate public company ...

Quoin Pharmaceuticals received European orphan drug designation for QRX003, supporting development for Peeling Skin Syndrome ...

Ocugen granted Roots Pharmaceutical regional rights to OCU400 for retinitis pigmentosa in the Middle East and North Africa ...